sab-176
Biologicalexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 29, 2020 (NCT04471038)
Timeline
Indications
Mechanism of action
- Influenza A virusImmunity, passive
Influenza A virus immunity, passive
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095290 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06435936 | Phase 1 | Apr 22, 2024 | SAB Biotherapeutics |
| NCT04850898 | Phase 2 | Jun 23, 2021 | hVIVO Services Limited, SAB Biotherapeutics |
| NCT04471038 | Phase 1 | Jul 29, 2020 | PPD, SAB Biotherapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SAB Biotherapeutics | For profit | 3 | 3 | 2 | 2020 |
| hVIVO Services Limited | For profit | 1 | 0 | 1 | 2021 |
| PPD | For profit | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1